BioCentury | Sep 10, 2001
Company News

Calydon, Cell Genesys deal

...CEGE completed its acquisition of private cancer company Calydon for 935,000 CEGE shares valued at $17...
...valued at $17 million based on CEGE's Friday close at $18.20 (see BioCentury, Aug. 6). Calydon Inc....
BioCentury | Sep 10, 2001
Analyst Picks & Changes

Analyst picks & changes

...his price target to $30-$32 from $24-$26. He said CEGE's completion of its acquisition of Calydon...
BioCentury | Aug 6, 2001
Company News

Calydon, Cell Genesys deal

...CEGE will acquire Calydon for about 935,000 CEGE shares valued at $17.4 million based on a...
...assume $2.6 million in Calydon liabilities, said the acquisition expands CEGE's cancer product pipeline with Calydon's...
...CV706. CV706 is expected to enter Phase III testing for early-stage prostate cancer in 2002. Calydon Inc....
BioCentury | Aug 2, 2001
Company News

Cell Genesys to acquire Calydon

...CEGE will acquire Calydon (Sunnyvale, Calif.) for about 935,000 CEGE shares valued at $17.4 million based...
...assume $2.6 million in Calydon liabilities, said the acquisition expands CEGE's cancer product pipeline with Calydon's...
BioCentury | Jul 2, 2001
Company News

Triad management update

...Calif. Business: Chemistry Hired: Christine Gray-Smith as CFO, formerly VP of finance and CFO at Calydon Inc. WIR...
BioCentury | Jan 22, 2001
Company News

Calydon other research news

...replicate, or that CV787 and the taxanes act in the same cancer cell apoptotic pathway. Calydon Inc....
BioCentury | Dec 18, 2000
Clinical News

Tumor-specific viruses regulatory update

...and a human glandular kallikrein enhancer (GKE) that regulate expression of genes in prostate cells. Calydon...
...replicate in and kill prostate cancer cells, or for screening compounds to treat prostate cancer. Calydon Inc....
BioCentury | Oct 30, 2000
Clinical News

CN706: Phase I/II

...second generation engineered virus is in separate Phase I/II testing to treat metastatic prostate cancer. Calydon Inc....
BioCentury | Oct 2, 2000
Clinical News

CV787: Began Phase I/II study

...containing human prostate-specific enhancer/promoter and rat probasin promoter elements Indication: Treat metastatic prostate cancer Status: Calydon...
BioCentury | Sep 11, 2000
Company News

Cell Genesys management update

...diseases Hired: Robert Tidwell as VP of corporate development, formerly VP of business development at Calydon Inc....
Items per page:
1 - 10 of 26
BioCentury | Sep 10, 2001
Company News

Calydon, Cell Genesys deal

...CEGE completed its acquisition of private cancer company Calydon for 935,000 CEGE shares valued at $17...
...valued at $17 million based on CEGE's Friday close at $18.20 (see BioCentury, Aug. 6). Calydon Inc....
BioCentury | Sep 10, 2001
Analyst Picks & Changes

Analyst picks & changes

...his price target to $30-$32 from $24-$26. He said CEGE's completion of its acquisition of Calydon...
BioCentury | Aug 6, 2001
Company News

Calydon, Cell Genesys deal

...CEGE will acquire Calydon for about 935,000 CEGE shares valued at $17.4 million based on a...
...assume $2.6 million in Calydon liabilities, said the acquisition expands CEGE's cancer product pipeline with Calydon's...
...CV706. CV706 is expected to enter Phase III testing for early-stage prostate cancer in 2002. Calydon Inc....
BioCentury | Aug 2, 2001
Company News

Cell Genesys to acquire Calydon

...CEGE will acquire Calydon (Sunnyvale, Calif.) for about 935,000 CEGE shares valued at $17.4 million based...
...assume $2.6 million in Calydon liabilities, said the acquisition expands CEGE's cancer product pipeline with Calydon's...
BioCentury | Jul 2, 2001
Company News

Triad management update

...Calif. Business: Chemistry Hired: Christine Gray-Smith as CFO, formerly VP of finance and CFO at Calydon Inc. WIR...
BioCentury | Jan 22, 2001
Company News

Calydon other research news

...replicate, or that CV787 and the taxanes act in the same cancer cell apoptotic pathway. Calydon Inc....
BioCentury | Dec 18, 2000
Clinical News

Tumor-specific viruses regulatory update

...and a human glandular kallikrein enhancer (GKE) that regulate expression of genes in prostate cells. Calydon...
...replicate in and kill prostate cancer cells, or for screening compounds to treat prostate cancer. Calydon Inc....
BioCentury | Oct 30, 2000
Clinical News

CN706: Phase I/II

...second generation engineered virus is in separate Phase I/II testing to treat metastatic prostate cancer. Calydon Inc....
BioCentury | Oct 2, 2000
Clinical News

CV787: Began Phase I/II study

...containing human prostate-specific enhancer/promoter and rat probasin promoter elements Indication: Treat metastatic prostate cancer Status: Calydon...
BioCentury | Sep 11, 2000
Company News

Cell Genesys management update

...diseases Hired: Robert Tidwell as VP of corporate development, formerly VP of business development at Calydon Inc....
Items per page:
1 - 10 of 26